JP3204456B2 - ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体 - Google Patents

２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体

Info

Publication number
JP3204456B2
JP3204456B2 JP52344697A JP52344697A JP3204456B2 JP 3204456 B2 JP3204456 B2 JP 3204456B2 JP 52344697 A JP52344697 A JP 52344697A JP 52344697 A JP52344697 A JP 52344697A JP 3204456 B2 JP3204456 B2 JP 3204456B2
Authority
JP
Japan
Prior art keywords
compound
pyrrolo
octahydro
pyrazine
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP52344697A
Other languages
English (en)
Japanese (ja)
Other versions
JPH11508920A (ja
Inventor
サンナー，マーク・エイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp SRL
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Publication of JPH11508920A publication Critical patent/JPH11508920A/ja
Application granted granted Critical
Publication of JP3204456B2 publication Critical patent/JP3204456B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Toxicology (AREA)
  • Addiction (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
JP52344697A 1995-12-21 1996-11-06 ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体 Expired - Fee Related JP3204456B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US898895P 1995-12-21 1995-12-21
US60/008,988 1995-12-21
PCT/IB1996/001192 WO1997023482A1 (en) 1995-12-21 1996-11-06 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives

Publications (2)

Publication Number Publication Date
JPH11508920A JPH11508920A (ja) 1999-08-03
JP3204456B2 true JP3204456B2 (ja) 2001-09-04

Family

ID=21734893

Family Applications (1)

Application Number Title Priority Date Filing Date
JP52344697A Expired - Fee Related JP3204456B2 (ja) 1995-12-21 1996-11-06 ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体

Country Status (33)

Country Link
US (1) US5714487A (en:Method)
EP (1) EP0874849B1 (en:Method)
JP (1) JP3204456B2 (en:Method)
KR (1) KR100286786B1 (en:Method)
CN (1) CN1061350C (en:Method)
AR (1) AR005102A1 (en:Method)
AT (1) ATE205846T1 (en:Method)
AU (1) AU704578B2 (en:Method)
BR (1) BR9612246A (en:Method)
CA (1) CA2240594C (en:Method)
CO (1) CO4480107A1 (en:Method)
CZ (1) CZ192998A3 (en:Method)
DE (1) DE69615404T2 (en:Method)
DK (1) DK0874849T3 (en:Method)
ES (1) ES2161377T3 (en:Method)
GR (1) GR3037060T3 (en:Method)
GT (1) GT199600101A (en:Method)
HU (1) HUP9900611A3 (en:Method)
IL (1) IL124453A0 (en:Method)
MA (1) MA26413A1 (en:Method)
MX (1) MX9805088A (en:Method)
NO (1) NO309936B1 (en:Method)
NZ (1) NZ320537A (en:Method)
PE (1) PE25998A1 (en:Method)
PL (1) PL327539A1 (en:Method)
PT (1) PT874849E (en:Method)
RU (1) RU2162470C2 (en:Method)
SI (1) SI0874849T1 (en:Method)
TN (1) TNSN96164A1 (en:Method)
TR (1) TR199801161T2 (en:Method)
TW (1) TW479058B (en:Method)
WO (1) WO1997023482A1 (en:Method)
ZA (1) ZA9610781B (en:Method)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461269B1 (en) 1999-09-10 2002-10-08 Mitsubishi Jidosha Kogyo Kabushiki Kaisha Continuously variable transmission

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
EP0982030A3 (en) 1998-08-17 2000-05-10 Pfizer Products Inc. 2,7-substituted octahydro-pyrrolo 1,2-a]pyrazine derivatives as 5ht 1a ligands
AU767089B2 (en) * 1999-02-05 2003-10-30 Pharmacia & Upjohn Company Process to prepare (5R)-(methylamino)-5,6-dihydro-4H- imidazo(4,5,1-ij)-quinolin-2(1H)-one
US7091199B1 (en) 1999-09-14 2006-08-15 Aventis Pharmaceuticals Inc. Thienoisoxazole phenoxy unsubstituted ethyl and propyl derivatives useful as d4 antagonists
US7253165B2 (en) 1999-09-14 2007-08-07 Aventis Pharmaceuticals Inc. Benzisoxazolyl-, pyridoisoxazolyl-and benzthienyl-phenoxy derivatives useful as D4 antagonists
MXPA02002694A (es) * 1999-09-14 2002-07-30 Aventis Pharm Prod Inc Derivados de benzisoxazolil-, piridoisoxazolil-y benzotienil-fenoxi utiles como antagonistas de d4.
US7125903B1 (en) 1999-09-14 2006-10-24 Aventis Pharmaceuticals Inc. Thienoisoxazolyl-and thienylpyrrazolyl-phenoxy substituted propyl derivatives useful as D4 antagonists
AU2002331229B2 (en) * 2001-09-19 2008-05-15 Merck Patent Gmbh Novel use of substituted aminomethyl chromans
TW200801005A (en) * 2005-08-15 2008-01-01 Astrazeneca Ab Acetylenic piperazines as metabotropic glutamate receptor antagonists
US7728031B2 (en) * 2006-02-24 2010-06-01 Abbott Laboratories Octahydro-pyrrolo[3,4-b]pyrrole derivatives
WO2013049164A1 (en) * 2011-09-29 2013-04-04 Abbvie Inc. SUBSTITUTED OCTAHYDROPYRROLO[1,2-a]PYRAZINES AS CALCIUM CHANNEL BLOCKERS
AU2019336671B2 (en) * 2018-09-04 2025-06-05 Contineum Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists
US11752149B2 (en) 2019-12-02 2023-09-12 Pipeline Therapeutics, Inc. Muscarinic acetylcholine M1 receptor antagonists

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4400511A (en) * 1982-05-07 1983-08-23 American Home Products Corporation 2-Substituted octahydropyrrolo(1,2-A)-pyrazine-3-carboxylic acids
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
US5122515A (en) * 1990-06-19 1992-06-16 Smith Ross C Nutrient composition containing dipeptides and method for administering the same
JP3058945B2 (ja) * 1990-10-26 2000-07-04 三共株式会社 Ｎ−（３，３−ジ置換アクリロイル）ピペラジン誘導体
CA2146018A1 (en) * 1992-10-23 1994-05-11 Paul David Leeson Dopamine receptor subtype ligands
ES2133416T3 (es) * 1992-10-23 1999-09-16 Merck Sharp & Dohme Ligandos de subtipos de receptores de dopamina.
WO1996004250A1 (en) * 1994-08-05 1996-02-15 Pfizer Inc. Benzimidazole derivatives having dopaminergic activity
EP0783503B1 (en) * 1994-09-30 2001-11-28 Pfizer Inc. 2,7-substituted octahydro-1h-pyrido[ 1,2-a]pyrazine derivatives
US5576314A (en) * 1994-12-12 1996-11-19 Allelix Biopharmaceuticals Inc. Bicyclic nonane and decane compounds having dopamine receptor affinity

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6461269B1 (en) 1999-09-10 2002-10-08 Mitsubishi Jidosha Kogyo Kabushiki Kaisha Continuously variable transmission

Also Published As

Publication number Publication date
PT874849E (pt) 2002-01-30
TW479058B (en) 2002-03-11
TNSN96164A1 (fr) 2005-03-15
US5714487A (en) 1998-02-03
ES2161377T3 (es) 2001-12-01
GT199600101A (es) 1998-06-12
DE69615404T2 (de) 2002-06-06
CN1205704A (zh) 1999-01-20
CO4480107A1 (es) 1997-07-09
TR199801161T2 (xx) 1998-10-21
CZ192998A3 (cs) 1999-05-12
EP0874849B1 (en) 2001-09-19
DK0874849T3 (da) 2001-11-19
AU7328096A (en) 1997-07-17
NO309936B1 (no) 2001-04-23
CN1061350C (zh) 2001-01-31
IL124453A0 (en) 1998-12-06
NO982843D0 (no) 1998-06-19
ZA9610781B (en) 1998-06-22
SI0874849T1 (en:Method) 2001-12-31
EP0874849A1 (en) 1998-11-04
BR9612246A (pt) 1999-07-13
NZ320537A (en) 1999-03-29
PL327539A1 (en) 1998-12-21
MA26413A1 (fr) 2004-12-20
NO982843L (no) 1998-06-19
KR100286786B1 (ko) 2001-04-16
WO1997023482A1 (en) 1997-07-03
DE69615404D1 (de) 2001-10-25
HUP9900611A3 (en) 2000-09-28
CA2240594A1 (en) 1997-07-03
CA2240594C (en) 2001-07-24
RU2162470C2 (ru) 2001-01-27
MX9805088A (es) 1998-10-31
KR19990076616A (ko) 1999-10-15
ATE205846T1 (de) 2001-10-15
PE25998A1 (es) 1998-05-19
AR005102A1 (es) 1999-04-14
HUP9900611A2 (hu) 1999-08-30
JPH11508920A (ja) 1999-08-03
AU704578B2 (en) 1999-04-29
GR3037060T3 (en) 2002-01-31

Similar Documents

Publication Publication Date Title
CN108349981B (zh) 新型的吡唑并[3，4－d]嘧啶化合物或其盐
US7361671B2 (en) Substituted heteroarylalkanoic acids
JP3204456B2 (ja) ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
WO1999048492A1 (en) Amide derivatives and nociceptin antagonists
WO2007055418A1 (ja) アザ置換スピロ誘導体
CN101686952A (zh) 新型钙离子通道调节剂
JPWO2014069510A1 (ja) 新規アミン誘導体またはその塩
JP2002507611A (ja) イミダゾロン食欲抑制薬：ｉｉ．フェニル誘導体
JP2005502662A (ja) ホスホジエステラーゼ阻害剤としての１−アルキルまたは１−シクロアルキルトリアゾロ［４，３−ａ］キナゾリン−５−オン類
CN101679272B (zh) 作为腺苷a3受体配体的三唑并[1,5-a]喹啉类
CN115413279A (zh) P2x3调节剂
EP2253632B1 (en) Pyrazolopyramidinone derivatives, their preparation and their use
SK12452003A3 (sk) Derivát fenylheterocyklyléteru ako inhibítor reabsorpcie serotonínu, jeho použitie a farmaceutický prostriedok, ktorý ho obsahuje
KR20000048899A (ko) 1,4-디치환 피페라진
US20090093476A1 (en) Pyrrolo[1,2-a]quinoxaline derivatives as adenosine a3 receptor modulators and uses thereof
US10519105B2 (en) KCNQ2-5 channel activator
CN106749045A (zh) 一种新型d‑氨基酸氧化酶抑制剂及其制法和应用
CN1248971A (zh) 喹喔啉二酮
CN101809014A (zh) 吡唑-3-基-苯甲酰胺衍生物的制造方法
WO2023061492A1 (zh) 2-氧代-3-氮杂双环[3.1.0]己烷衍生物
CN1830978B (zh) 吡唑并[4,3-c]喹啉-3-酮化合物、其制备方法及其应用
FR2838124A1 (fr) Derives de 3-heteroaryl-3,5-dihydro-4-oxo-4h-pyridazino [4,5-b]indole-1-acetamide, leur preparation et leur application en therapeutique
CN121226330A (zh) 取代的哌啶类化合物及其药物组合物、制备方法和用途
CN107304180B (zh) 苯甲酰胺类衍生物、其制备方法及其在医药上的用途

Legal Events

Date Code Title Description
R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees